bioihbjkbjnl/mcl2 huggingface dataset:
The Relationship of Shear Wave Elastography Findings With Pain Threshold and Quality of Life in Patients With Lipedema
Condition: Pain; Lipedema
MeSH terms: Lipedema
Study type: Observational [Patient Registry]

Summary: 
      The aim of this study is to evaluate the relationship between disease severity and
      subcutaneous tissue shearwave elastography findings with pain threshold and quality of life
      in patients diagnosed with lipedema.
    

Detailed description: 
      Patients diagnosed with lipedema were divided into 3 stages according to disease severity.
      Pain level was evaluated with visual analogue scale, pain threshold with algometric
      measurement, and quality of life with EQ-5D general quality of life scale. All patients
      underwent measurements using B-mode ultrasound and subcutaneous elastic modulus with shear
      wave elastography (SWE) imaging of lower limbs at three anatomical levels.
    

Intervention name(s): SWE:B-mode ultrasound and subcutaneous elastic modulus with shear wave elastography at three level
Intervention type(s): Diagnostic Test
Intervention description(s): Visual analog scale(VAS):This scale measure in which individuals rate their pain from 0 to 10, with 0 indicating no pain at all and 10 representing the worst pain;pain threshold through algometric measurement; quality of life using the EQ-5D general quality of life scale.
Other intervention name(s): visual analog scale(VAS); pain threshold through algometric measurement; EQ-5D general quality of life scale.
Observational model: Other
Time perspective: Cross-Sectional
Sampling method: Non-Probability Sample
Study population: 
        The study consist of female patients aged 18-70, diagnosed with lipedema
      
Keywords: Shear Wave Elastography; Pain; Lipedema
Ulinastatin Improves Postoperative Oxygenation After Cardiopulmonary Bypass
Condition: Cardiopulmonary Bypass; Cardiac Surgery
Study type: Interventional
Phase: Phase 4

Summary: 
      Retrospective study determine whether ulinastatin enhances postoperative pulmonary
      oxygenation after cardiopulmonary bypass (CPB).
    

Detailed description: 
      This retrospective study evaluate patients who underwent aortic valvular surgery under
      moderate hypothermic CPB. The patients were classified into two groups: patients in whom
      high-dose ulinastatin (10,000 U/kg and 5,000 U/kg/h) was administered during CPB (Group-U);
      and patients in whom ulinastatin was not administered (Group-C). We measured PaO2/FiO2 at the
      following time points: before CPB (Pre-CPB), 2 hours after weaning from CPB (Post-CPB) and
      within 6 hours after admission to the ICU. The lengths of ventilator care and ICU stay were
      also reviewed.
    

Intervention name(s): ulinastatin; control
Intervention type(s): Drug; Drug
Intervention description(s): ulinastatin (10000 U/kg and 5000 U/kg/h) was administered during CPB; conventional CPB was applied without ulinastatin treatment
Other intervention name(s): ulinastatin administration; placebo
Intervention MeSH terms: Urinastatin
Allocation: Non-Randomized
Intervention model: Parallel Assignment
Intervention model description: Retrospective cohort study
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: ulinastatin; cardiopulmonary bypass; cardiac surgery
Use of Low-dose Zolpidem in Parkinson's Disease
Condition: Parkinson Disease
MeSH terms: Parkinson Disease
Study type: Interventional
Phase: Phase 2

Summary: 
      This study will evaluate the motor and cognitive benefits of low-dose zolpidem in
      Parkinson's.
    

Detailed description: 
      Zolpidem is a hypnotic drug which at sub-sedative doses has been shown to improve both motor
      and cognitive deficits in stroke, dementia and Parkinson's. This has led to the hypothesis
      that low-dose zolpidem will be effective in early-stage Parkinson's, delaying the need for
      dopamine-replacement interventions, as an adjunct therapy, and in late-stage Parkinson's
      where current interventions are ineffective for motor and cognitive decline. At present, the
      symptoms of late-stage Parkinson's are the most debilitating and the least well-controlled.
      Here, the investigators propose a placebo controlled double-blinded proof-of-concept study in
      order to determine the benefits of taking low-dose zolpidem in late-stage Parkinson's. The
      study will take place over 12 months. 28 participants, diagnosed with Parkinson's for at
      least 5 years will be recruited; 14 participants will take zolpidem (5 mg) and 14 placebo,
      each morning for 4 days. In the clinic (day 1) clinical assessments will include the motor
      III of the Unified Parkinson's Disease Rating Scale (UPDRS) and cognitive verbal fluency
      tasks which will be conducted at baseline and 1 hour following drug administration. Each
      participant will then be issued with a smartphone with application to objectively test their
      motor performance 4 times a day, over the next six days (3 days on drug, 3 days off drug).
      This study will provide the necessary data on drug efficacy in order to design a phase II
      clinical trial for the use of low-dose zolpidem in late-stage Parkinson's.
    

Intervention name(s): Zolpidem; Placebo
Intervention type(s): Drug; Other
Intervention description(s): Zolpidem is a non-benzodiazepine sedative/hypnotic agent usually prescribed for insomnia.; Placebo
Other intervention name(s): Stilnoct
Intervention MeSH terms: Zolpidem
Allocation: Randomized
Intervention model: Parallel Assignment
Intervention model description: A placebo controlled double-blinded proof-of-concept study
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Treatment
Keywords: motor;; cognition
A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities
Condition: Obesity; Overweight and Obesity
MeSH terms: Obesity; Overweight
Study type: Interventional
Phase: Phase 2

Summary: 
      The main purpose of the study was to assess the effect of LY3502970 in participants who have
      obesity or are overweight.
    


Intervention name(s): LY3502970; Placebo
Intervention type(s): Drug; Drug
Intervention description(s): Administered orally; Administered orally
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Treatment
Educational Intervention to Improve Vaccine Acceptance
Condition: Vaccine Hesitancy
Study type: Interventional

Summary: 
      This research project will develop an educational intervention to improve immunization
      acceptance by vaccine hesitant parents. This is prospective interventional case-control
      trial, where the investigators will provide the intervention in the clinical setting.
      Enrollees will be screened and selected if they meet criteria for "vaccine hesitancy". The
      investigators will conduct follow up surveys following the intervention to assess change in
      attitude and follow immunization rates through 18 month well visit.
    

Detailed description: 
      The intervention is a 8 minute video addressing common concerns that have been reported by
      vaccine hesitant parents. The video includes an expert in pediatric infectious diseases
      answering these common questions as well as 3 parental accounts of children who contracted
      vaccine preventable diseases. Also, the interventional group will be provided with two
      handouts: one listed information on how parents can find accurate vaccine information on the
      internet, and another that addresses more common concerns of vaccine hesitant parents and
      available for our use from the Children's Hospital of Philadelphia Vaccine Center website.
    

Intervention name(s): Video intervention along with educational hand out
Intervention type(s): Other
Intervention description(s): The interventional group will be shown an 8 minute video addressing common concerns of vaccine hesitant parents. Then, they will be provided with a handout describing how to find accurate vaccine information on the internet and a handout on more common questions from vaccine hesitant parents.
Allocation: Randomized
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Prevention
Effect of MAXOMAT ® on the Growth of Small Children to NOONAN's Syndrome
Condition: Noonan Syndrome
MeSH terms: Noonan Syndrome; Syndrome
Study type: Interventional
Phase: Phase 3

Summary: 
      1. Clinical Objective : To improve the growth of these children

        2. Genetic objective : A study of the genetics of the syndrome
    


Intervention name(s): MAXOMAT ®, biosynthetic growth hormone
Intervention type(s): Drug
Intervention description(s): 2 posologies according to age (children and adolescents) treatment is planned for a 2 year duration
Intervention MeSH terms: Hormones
Allocation: Non-Randomized
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease
Condition: NAFLD; Diabetes Mellitus, Type 2; Hypertriglyceridemia; Fatty Liver, Nonalcoholic
MeSH terms: Liver Diseases; Fatty Liver; Non-alcoholic Fatty Liver Disease; Diabetes Mellitus; Diabetes Mellitus, Type 2; Hypertriglyceridemia
Study type: Interventional
Phase: Phase 2

Summary: 
      This is a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to
      evaluate the safety, including tolerability, of ISIS 703802 and to assess the efficacy of
      different doses and dosing regimens of ISIS 703802 on glucose and lipid metabolism, and liver
      fat in participants with hypertriglyceridemia, Type 2 diabetes mellitus (T2DM), and
      nonalcoholic fatty liver disease (NAFLD).
    


Intervention name(s): Placebo; ISIS 703802 40 mg; ISIS 703802 80 mg; ISIS 703802 20 mg
Intervention type(s): Drug; Drug; Drug; Drug
Intervention description(s): Placebo (Matched with ISIS 703802); ISIS 703802 40 mg, administered via SC injection, once every 4 weeks for 6 doses.; ISIS 703802 80 mg, administered via SC injection, once every 4 weeks for 6 doses.; ISIS 703802 20 mg, administered via SC injection, once every week for 26 doses.
Other intervention name(s): Sterile Normal Saline (0.9% NaCl); AKCEA-ANGPTL3-LRx; IONIS-ANGPTL3-LRx; Vupanorsen; AKCEA-ANGPTL3-LRx; IONIS-ANGPTL3-LRx; Vupanorsen; AKCEA-ANGPTL3-LRx; IONIS-ANGPTL3-LRx; Vupanorsen
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary purpose: Treatment
Keywords: Type 2 Diabetes; Hepatic Steatosis; Triglycerides; AKCEA-ANGPTL3-Lrx; IONIS-ANGPTL3-Lrx; Fatty Liver; Fatty Liver Without Mention of Alcohol; Liver Fat; Liver Diseases; Diabetes Mellitus Type 2 in Nonobese; Diabetes Mellitus; Triglycerides High; High Triglycerides; Metabolic Disease; Endocrine System Diseases; Digestive System Disease; Glucose Metabolism Disorders; Vupanorsen
Amylase and Hypersomnia
Condition: Hypersomnia in Children
MeSH terms: Disorders of Excessive Somnolence
Study type: Interventional

Summary: 
      Hypersomnia is defined as a reduced ability to remain awake during the day. There are
      basically two types of central hypersomnia: narcolepsy and idiopathic hypersomnia. Currently,
      the diagnosis of these sleep disorders is based on polysomnographic recordings which is
      difficult to access. Tests of sleepiness (Epworth, Karolinska) are subjective.

      A biological marker of sleepiness, easily accessible and measurable, would be very useful for
      the diagnosis and therapeutic follow up of excessive diurnal sleepiness. Salivary secretions
      appear as good physiological markers. Studies have shown for healthy subjects, that the
      expression and activity of salivary amylase are increased when subjects are deprived of
      sleep.

      The investigators propose to explore the usefulness of salivary biomarkers (including
      amylase) as a new non-invasive and simple technique for the assessment of excessive daytime
      sleepiness.
    


Intervention name(s): saliva collection
Intervention type(s): Procedure
Intervention description(s): collection of saliva
Allocation: Non-Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Other
Keywords: hypersomnia; narcolepsy; amylase; salivary sampling
A Study to Evaluate the Combination of Cetuximab and Chemotherapy as Neoadjuvant Therapy Followed Concomitant Chemoradiotherapy Plus Cetuximab in Locoregional Esophageal Carcinoma
Condition: Esophageal Carcinoma
MeSH terms: Carcinoma; Esophageal Neoplasms
Study type: Interventional
Phase: Phase 2

Summary: 
      The purpose of the study is to determine efficacy ans safety of the combination of cetuximab
      and chemotherapy (docetaxel, cisplatin, 5-fluorouracil) as neoadjuvant therapy followed
      concomitant chemoradiotherapy (cisplatin) plus cetuximab in patients with a locoregional
      esophageal carcinoma
    


Intervention name(s): cetuximab and chemotherapy (docetaxel, cisplatin, 5-fluorouracil)
Intervention type(s): Drug
Intervention description(s): Neoadjuvant chemotherapy plus cetuximab:
3 cycles of chemotherapy (Docetaxel: 75 mg/m2; day1; Cisplatin :75 mg/m2, day 1; 5-FU: 750 mg/m2; 24-hour infusion; day1-5) administered every 3 weeks, plus cetuximab (250 mg/m2; day 1, 8 and 15) Cetuximab will be maintained from the beginning of chemotherapy until the end of radiotherapy.
Radio-chemotherapy plus cetuximab:
The radiotherapy treatment: A dose of 50.4 Gy will be administered in 28 fractions of 1.8 Gy / day, 5 days a week (a total of 5.6 weeks).
Cetuximab:250 mg/m2 and Cisplatin: 40 mg/m2, day 1, 8, 15, 22, 29 and 36
Intervention MeSH terms: Docetaxel; Fluorouracil; Cetuximab
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: esophageal carcinoma; cetuximab; docetaxel; cisplatin; 5-fluorouracil
Assessment of Asthma Mimics Among Newly Diagnosed Bronchial Asthma Patients
Condition: Asthma (Diagnosis)
MeSH terms: Asthma
Study type: Interventional

Summary: 
      The aim of the study was to identify the percentage of patients in whom the diagnosis of
      current asthma was confirmed or ruled out after clinical, spirometric assessment and
      utilizing all the possible investigations with a six month follow up period for both groups.
    

Detailed description: 
      The diagnosis of bronchial asthma relies on the existence of characteristic respiratory
      symptoms which are reversible and variable (diurnal and seasonal) with variable airflow
      limitation. Unfortunately, bronchial asthma may mimic different pulmonary and non-pulmonary
      diseases regarding their similar clinical presentations so accurate assessment is required to
      exclude other possible diagnosis before confirming the diagnosis of bronchial asthma.

      There are various phenotypes of asthma as; atopic, non-atopic, and late-onset asthma, which
      may not be easily diagnosed in the community. Also, asthma may show intermittent versus a
      relapsing /remitting course, so it is difficult to be diagnosed by a single physician visit.
      Different studies have found that patients with bronchial asthma were treated empirically
      without full assessment either to ensure or exclude the asthma diagnosis.

      Some symptoms as chest wheezes and breathlessness may be presented commonly in bronchial
      asthma and other mimic diseases as; chronic obstructive pulmonary disease, bronchiectasis,
      congestive heart failure, vocal cord disorders, hypersensitivity pneumonitis, endobronchial
      tumours, pulmonary embolism, aspiration syndromes, tracheal compression by a mediastinal mass
      and tracheomalacia. So, different physicians should put in mind those asthma mimics to be
      differentiated from asthmatic patients specially whose asthma symptoms are poorly controlled
      by anti- asthmatic medications.
    

Intervention name(s): Fibreoptic bronchoscopy
Intervention type(s): Device
Intervention description(s): different endoscopies used for confirmation of diagnosis
Other intervention name(s): Upper Gastrointestinal (GI) endoscopy
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Diagnostic
Keywords: asthma, mimic diseases, spirometry
MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2)
Condition: Type 2 Diabetes Mellitus
MeSH terms: Diabetes Mellitus; Diabetes Mellitus, Type 2
Study type: Interventional
Phase: Phase 3

Summary: 
      A study to evaluate the efficacy and safety of sitagliptin and pioglitazone co-administration
      in comparison with sitagliptin and pioglitazone monotherapy in patients with type 2 diabetes.
    


Intervention name(s): Sitagliptin phosphate; Pioglitazone hydrochloride; Matching placebo to sitagliptin; Matching placebo to pioglitazone; Metformin
Intervention type(s): Drug; Drug; Drug; Drug; Drug
Intervention description(s): Sitagliptin 100 mg tablet (blinded) orally once daily for 54 weeks.; Pioglitazone 15 mg, 30 mg, or 45 mg tablets or capsules (blinded) orally once daily for 54 weeks. Participants randomized to receive pioglitazone 45 mg as monotherapy or in combination with sitagliptin were to start on pioglitazone 30 mg at Week 1 and undergo uptitration to pioglitazone 45 mg at Week 4.; Matching placebo to sitagliptin orally once daily for 54 weeks.; Matching placebo to pioglitazone tablets or capsules orally once daily for 54 weeks.; Metformin 500 mg (open-label) was to be initiated as rescue therapy to participants not meeting specific glycemic goals. The dose of metformin may have been uptitrated and adjusted, at the discretion of the investigator, up to the maximum approved dose in the country of origin.
Other intervention name(s): Januvia; Tesavel; Xelevia; Ristaben; Actos
Intervention MeSH terms: Metformin; Pioglitazone; Sitagliptin Phosphate
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Treatment
Effects of Kendall Exercise Versus Gong's Mobilization in Text Neck Syndrome. A Pilot Study
Condition: Neck Pain
MeSH terms: Neck Pain
Study type: Interventional

Summary: 
      This project was a pilot randomized trial conducted to compare the effects of Kendall
      exercise and Gong's mobilization on pain, range of motion, function and strength in text neck
      syndrome so that we can have best treatment option for patients with neck pain
    

Detailed description: 
      Non Probability Convenient sampling was done. Patients following eligibility criteria from
      Fatima hospital Sargodha were considered. Sample size was calculated 12.

      Participants were randomly allocated in two groups equally via convenient sampling method.
      Baseline assessment was done initially. Group A was given Kendall exercise and Group B was
      given Gong's mobilization along with conventional physiotherapy treatment (hot pack).
      Duration of research was almost 6 months. Participants were treated 3 times a week for 4
      weeks. Pre and Post treatment readings were taken in 1st session and 4th week period
      respectively.

      Assessment was done via Numeric pain rating scale (NPRS),Neck Disability index (NDI),
      Universal goniometer and Modified sphygmomanometer test. All participants were provided
      written informed consent prior to commencement of the procedures. They were free to quit the
      treatment at any stage of research. Data was analyzed by using SPSS version 23.
    

Intervention name(s): Kendall exercise; Gong's mobilization
Intervention type(s): Other; Other
Intervention description(s): consist of stretch of pectoralis major and neck extensor strengthening of deep neck flexors and scapular retractor; it is combination of glide along the facet joint and concurrent movement of cervical spine
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary purpose: Treatment
Keywords: neck pain
Chronic Kidney Disease Prevention of An-Lo District, Keelung
Condition: Chronic Kidney Disease; End Stage Renal Disease; Death
MeSH terms: Kidney Diseases; Renal Insufficiency, Chronic; Kidney Failure, Chronic
Study type: Interventional
Phase: Phase 4

Summary: 
      The prevalence and the incidence of the end-stage renal disease (ESRD) are extremely high in
      Taiwan (1, 2). More than 45,000 patients are under renal replacement therapy in the year 2004
      (2). The disease had not only caused a significant impact in personal life, but also a great
      burden on social security and government-run health insurance. However, despite this high
      prevalence, the awareness of chronic kidney disease (CKD) in general population remains low
      (3, 4). The patients always come out too late for the intervention to slow down the
      progression of renal failure. Furthermore, most of them are not well prepared for the renal
      replacement therapy. The facts result in high mortality and morbidity in this specific
      population (5). It is mandatory to screen out and treat these patients early enough. However,
      these patients are deep into the community as the asymptomatic nature of CKD.

      The major purpose of the study is to screen the community for the early CKD and provide the
      appropriate intervention at time. The study will collect the characteristic demographic
      epidemiological data and find out risk factors for CKD of this geographic area, provide
      multidisciplinary education of CKD and establish timely referral for appropriate nephrologist
      care for treatment and monitoring of complications.
    

Detailed description: 
      The project will be last for 3 years. We will start to screen the patients within the
      community to identify the CKD population. This population will randomized into two group (one
      group with standard nephrologist care and another group with standard nephrologist care plus
      multidisciplinary CKD education) to evaluate the effectiveness of CKD education on the
      progression of renal function. The primary end-point will be the doubling tine estimated GFR,
      development of end-stage renal disease and all cause mortality. The non-CKD group of
      community will also follow up for urine and blood test for renal function, to determine the
      incidence and risk factors of new-onset renal disease. The accomplishment of this study will
      retard renal progression, improve community health and establish a model in preventing the
      chronic kidney disease.
    

Intervention name(s): multidisciplinary predialysis education
Intervention type(s): Behavioral
Intervention description(s): teaching of renal knowledges, dietary support and recall of period medical visits
Other intervention name(s): MPE
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Prevention
Keywords: Chronic Kidney Disease; Prevention; Cardiovascular disease